Alongside cagrilintide, our metabolic research catalog includes Semaglutide (GLP-1 monoagonist), Tirzepatide (GLP-1/GIP dual agonist), Retatrutide (GLP-1/GIP/glucagon triagonist), AOD-9604 (hGH lipolytic fragment), MOTS-C (mitochondrial metabolic regulator), and 5-Amino-1MQ (NNMT inhibitor)
Tirzepatide is a 39amino acid dual incretin receptor agonist that activates both GLP1 and GIP receptors, enhancing glucosedependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite [1] [2]
This has been the cause of the surging Tylenol autism lawsuits recently
Supplied strictly for laboratory and scientific research only
Side effects during the first week at 1.0 mg can be more noticeable than previous increases
PMID: 23250957